66346-53-0
5-Hydroxy-7-methyl-4-propyl-2H-chromen-2-one
CAS: 66346-53-0
Molecular Formula: C13H14O3
66346-53-0 - Names and Identifiers
66346-53-0 - Physico-chemical Properties
| Molecular Formula | C13H14O3 |
| Molar Mass | 218.25 |
| Density | 1.186±0.06 g/cm3(Predicted) |
| Melting Point | 180 °C |
| Boling Point | 390.2±42.0 °C(Predicted) |
| pKa | 7.60±0.20(Predicted) |
| Storage Condition | Room Temprature |
| Sensitive | IRRITANT |
| MDL | MFCD02080283 |
66346-53-0 - Risk and Safety
| Hazard Class | IRRITANT |
66346-53-0 - Introduction
It is also known as Fabafloxacin (Faproxifene), the chemical name for a compound. The following is a description of the properties, uses, preparation and safety information of the compound:
Nature:
-is a distinctive organic compound with the appearance of orange-yellow crystals
-It is an aromatic ketone compound and has the characteristics of a polycyclic structure (chromophore)
-Its chemical formula is C16H16O3, and its molecular weight is 256.3g/mol
-It is relatively stable under conventional conditions and soluble in some organic solvents such as ethanol and dimethyl sulfoxide
Use:
-The main use of the pill is as a medicine, especially in cancer treatment
-This compound is being studied for the treatment of anti-estrogen receptor-positive breast cancer patients and is able to interfere with the estrogen signaling pathway and inhibit cancer cell proliferation
-It may also have anti-tumor activity against other types of tumors, but more research and clinical trials are needed
Preparation Method:
-The preparation method of the pill can be achieved through synthetic organic synthetic chemical reactions
-The specific synthetic route may be different, but usually involves a series of chemical reaction steps, such as ketone synthesis, alkylation and hydrogenation, etc.
Safety Information:
-Most drug compounds have certain safety considerations
-Safety and toxicity data are often evaluated in clinical studies and trials
-Due to possible individual differences and rare abnormal reactions, the use and dosage of the compound should follow the doctor's advice to avoid improper use or abuse
-Strictly follow the safe operating procedures during use, avoid contact with skin and eyes, and avoid inhalation or ingestion
-In case of discomfort or suspected poisoning, seek medical help immediately and keep the dose or medication out of reach of the child.
Nature:
-is a distinctive organic compound with the appearance of orange-yellow crystals
-It is an aromatic ketone compound and has the characteristics of a polycyclic structure (chromophore)
-Its chemical formula is C16H16O3, and its molecular weight is 256.3g/mol
-It is relatively stable under conventional conditions and soluble in some organic solvents such as ethanol and dimethyl sulfoxide
Use:
-The main use of the pill is as a medicine, especially in cancer treatment
-This compound is being studied for the treatment of anti-estrogen receptor-positive breast cancer patients and is able to interfere with the estrogen signaling pathway and inhibit cancer cell proliferation
-It may also have anti-tumor activity against other types of tumors, but more research and clinical trials are needed
Preparation Method:
-The preparation method of the pill can be achieved through synthetic organic synthetic chemical reactions
-The specific synthetic route may be different, but usually involves a series of chemical reaction steps, such as ketone synthesis, alkylation and hydrogenation, etc.
Safety Information:
-Most drug compounds have certain safety considerations
-Safety and toxicity data are often evaluated in clinical studies and trials
-Due to possible individual differences and rare abnormal reactions, the use and dosage of the compound should follow the doctor's advice to avoid improper use or abuse
-Strictly follow the safe operating procedures during use, avoid contact with skin and eyes, and avoid inhalation or ingestion
-In case of discomfort or suspected poisoning, seek medical help immediately and keep the dose or medication out of reach of the child.
Last Update：2024-04-09 02:00:57
